Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/23/2025

INSTI Resistance Patterns in Dual NRTI + DTG Failure

Overall Assessment

  • The International AIDS Society-USA recommends that INSTI resistance remains uncommon overall, related to poor adherence and viremia at switch, with a high rate of pan-INSTI cross-resistance (68.9%) 1

Key Findings and Their Clinical Significance

  • The American College of Physicians suggests that subtype C shows G118R predominance (53.3% vs 21.7% in subtype B; p=0.019), which has profound implications for African settings where subtype C predominates and DTG is first-line therapy 1
  • The Centers for Disease Control and Prevention indicates that INSTI resistance emergence is predominantly high-level and pan-INSTI rather than low-level and drug-specific, with G118R conferring median 18.8-fold reduced DTG susceptibility compared to R263K's 2.0-fold reduction 1, 2

Critical Clinical Implications

  • The World Health Organization recommends that for patients on dual NRTI + DTG with NRTI resistance, viral load monitoring at 1 month, then every 3 months for the first year is mandatory, and any confirmed viremia >200 copies/mL should trigger immediate genotypic resistance testing 1, 2
  • The European AIDS Clinical Society suggests that for patients with detected INSTI DRMs, switching to another INSTI is contraindicated in the presence of G118R or Q148HRK + G140ACRS, and novel agents such as lenacapavir are recommended for multiclass resistance including INSTI resistance 2, 3

Salvage Therapy Considerations

  • The National Institutes of Health recommends that for patients with emergent INSTI resistance on dual NRTI + DTG, continue NRTIs despite resistance, as they retain partial activity, and consider fostemsavir or ibalizumab as part of a fully suppressive regimen 2, 3

Recommendations for Clinical Practice

  • The Infectious Diseases Society of America suggests that baseline resistance testing should be performed before initiating dual NRTI + DTG in treatment-experienced patients, and in resource-limited settings, prioritize resistance testing for patients with prior NRTI exposure or viremia >500,000 copies/mL 1
  • The American Academy of HIV Medicine recommends that treatment selection should avoid dual NRTI + DTG in patients with documented NRTI resistance unless no alternatives exist, and consider triple therapy with DTG + 2 NRTIs + boosted PI in high-risk patients 1, 2